Wedbush Comments on Immunome’s Q3 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – Stock analysts at Wedbush reduced their Q3 2025 earnings estimates for Immunome in a research note issued to investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.45). Wedbush currently has a “Outperform” rating and a $21.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome’s Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.04) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($0.21) EPS.

IMNM has been the subject of several other reports. JPMorgan Chase & Co. reduced their target price on Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.14.

Immunome Stock Performance

Shares of IMNM stock opened at $9.69 on Monday. The company has a market capitalization of $843.42 million, a PE ratio of -3.15 and a beta of 1.93. Immunome has a 52-week low of $5.15 and a 52-week high of $16.73. The business’s fifty day moving average is $9.55 and its 200 day moving average is $8.90.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of Immunome stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average cost of $9.38 per share, for a total transaction of $46,900.00. Following the transaction, the director owned 36,415 shares of the company’s stock, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.69% of the stock is currently owned by company insiders.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of IMNM. Teacher Retirement System of Texas raised its stake in shares of Immunome by 6.8% during the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after acquiring an additional 1,188 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Immunome by 3.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock valued at $470,000 after purchasing an additional 1,643 shares during the last quarter. Invesco Ltd. raised its position in Immunome by 6.4% in the 1st quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock worth $191,000 after purchasing an additional 1,718 shares during the period. Voya Investment Management LLC lifted its stake in Immunome by 21.2% in the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company’s stock worth $127,000 after purchasing an additional 3,305 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after purchasing an additional 4,874 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.